Spiegel at al. tested a bispecific CAR targeting CD19 and CD22 in a phase 1 clinical trial (NCT03233854) involving adults with r/r B-ALL and DLBCL. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.